Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Regeneron Pharmaceuticals
Bayer
Boehringer Ingelheim
Seagen Inc.
Iovance Biotherapeutics, Inc.
Pierre Fabre Ltd
Bristol-Myers Squibb
OncoC4, Inc.
Bristol-Myers Squibb
Genmab
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Genmab
USWM, LLC (dba US WorldMeds)
Pfizer
Pfizer
Iovance Biotherapeutics, Inc.
Pfizer
Bayer
iOnctura
Genentech, Inc.
BeOne Medicines
Hoffmann-La Roche
Novartis
Hoffmann-La Roche
Merck Sharp & Dohme LLC
TILT Biotherapeutics Ltd.
Erasca, Inc.
Erasca, Inc.
Novartis
IDEAYA Biosciences
Replimune, Inc.
Phio Pharmaceuticals Inc.
Regeneron Pharmaceuticals
Sapience Therapeutics
Sandoz
ModernaTX, Inc.
Novartis
iOnctura
ImmunityBio, Inc.
Amgen
AbbVie
AgonOx, Inc.
Novartis
Pierre Fabre Medicament
Syntrix Biosystems, Inc.
Amgen
Scancell Ltd
Inhibrx Biosciences, Inc